The pricing agreement in Regeneron Pharmaceuticals, Inc.’s COVID-19 deal with the US Biomedical Advanced Research and Development Authority (BARDA) is not groundbreaking, even though it jarred loose Monica Bertagnolli’s nomination for National Institutes of Health director.
However, including the clause in a contract funding more than product procurement may suggest that the US government is growing...






